Msd Sub Merck Drug Patent Portfolio
Msd Sub Merck owns 12 orange book drugs protected by 60 US patents with Steglatro having the least patent protection, holding only 1 patent. And Janumet Xr with maximum patent protection, holding 12 patents. Given below is the list of Msd Sub Merck's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10772888 | Solid pharmaceutical compositions containing an integrase inhibitor | 30 Mar, 2032 | Active |
| US8871759 | Inhibitors of hepatitis C virus replication | 04 May, 2031 | Active |
| US9649311 | Solid pharmaceutical compositions containing an integrase inhibitor | 21 Apr, 2031 | Active |
| US9649311 | Solid pharmaceutical compositions containing an integrase inhibitor | 21 Oct, 2030 | Active |
| US9308204 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | 21 Oct, 2030 | Active |
| US9439902 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | 21 Oct, 2030 | Active |
| US9439901 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | 21 Oct, 2030 | Active |
| US8080580 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | 13 Jul, 2030 | Active |
| US8771733 | Pharmaceutical composition containing an anti-nucleating agent | 02 Jun, 2030 | Active |
| US7754731 | Potassium salt of an HIV integrase inhibitor | 11 Sep, 2029 | Active |
| US7973040 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | 24 Jul, 2029 | Active |
| US7754731 | Potassium salt of an HIV integrase inhibitor | 11 Mar, 2029 | Active |
| US8414921 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin | 21 Jan, 2029 | Active |
| US8414921 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin | 21 Jul, 2028 | Active |
| US8450372 | Formulations of suberoylanilide hydroxamic acid and methods for producing same | 18 Mar, 2028 | Active |
| US8852632 | Pharmaceutical formulation containing a release rate controlling composition | 28 Jan, 2028 | Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | 24 May, 2027 | Active |
| US7456219 | Polymorphs of suberoylanilide hydroxamic acid | 11 Mar, 2027 | Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | 24 Nov, 2026 | Active |
| US8093295 | Formulations of suberoylanilide hydroxamic acid and methods for producing the same | 16 May, 2026 | Active |
| USRE44733 | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block | 27 Jan, 2026 | Active |
| US7399787 | Methods of treating cancer with HDAC inhibitors | 09 Feb, 2025 | Active |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 03 Apr, 2024 | Expired |
| US7851509 | Polymorphs of suberoylanilide hydroxamic acid | 21 Feb, 2024 | Expired |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 03 Oct, 2023 | Expired |
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Apr, 2023 | Expired |
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Apr, 2023 | Expired |
| US7652069 | Polymorphs of suberoylanilide hydroxamic acid | 04 Mar, 2023 | Expired |
| US7732490 | Methods of treating cancer | 04 Mar, 2023 | Expired |
| US8067472 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma | 04 Mar, 2023 | Expired |
| US8101663 | Polymorphs of suberoylanilide hydroxamic acid | 04 Mar, 2023 | Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jan, 2023 | Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jan, 2023 | Expired |
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Oct, 2022 | Expired |
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Oct, 2022 | Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jul, 2022 | Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jul, 2022 | Expired |
| US6949527 | 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block | 27 Jan, 2021 | Expired |
| US7265009 | HDP-CVD methodology for forming PMD layer | 07 Aug, 2020 | Expired |
| US7265099 | Use of chemical chelators as reversal agents for drug-induced neuromuscular block | 07 Aug, 2020 | Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US5952323 | Carbapenem antibiotic | 15 Nov, 2017 | Expired |
| US5952323 | Carbapenem antibiotic | 15 May, 2017 | Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals | 24 Apr, 2017 | Expired |
| US6340475 | Extending the duration of drug release within the stomach during the fed mode | 19 Sep, 2016 | Expired |
| US6635280 | Extending the duration of drug release within the stomach during the fed mode | 19 Sep, 2016 | Expired |
| US5478820 | Antibiotic compounds | 21 May, 2016 | Expired |
| US5478820 | Antibiotic compounds | 21 Nov, 2015 | Expired |
| US5807825 | Platelet aggregation inhibitors | 15 Sep, 2015 | Expired |
| US5968902 | Platelet aggregation inhibitors | 02 Jun, 2015 | Expired |
| US5747447 | Stable polypeptide composition | 05 May, 2015 | Expired |
| US5686570 | Platelet aggregation inhibitors | 11 Nov, 2014 | Expired |
| US5756451 | Platelet aggregation inhibitors | 11 Nov, 2014 | Expired |
| USRE38506 | Potent inducers of terminal differentiation and methods of use thereof | 29 Nov, 2013 | Expired |
| US5652233 | Antibiotic compounds | 02 Aug, 2013 | Expired |
| US7342005 | Antibiotic compounds | 02 Aug, 2013 | Expired |
| US5652233 | Antibiotic compounds | 02 Feb, 2013 | Expired |
| US7342005 | Antibiotic compounds | 02 Feb, 2013 | Expired |
Latest Legal Activities on Msd Sub Merck's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Msd Sub Merck.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 27 Jun, 2024 | US8080580 |
| transaction for FDA Determination of Regulatory Review Period | 27 Jun, 2024 | US8080580 |
| transaction for FDA Determination of Regulatory Review Period | 27 Jun, 2024 | US8080580 |
| Court Processing Terminated | 17 Apr, 2024 | US7326708 (Litigated) |
| Court Processing Terminated | 17 Apr, 2024 | US7326708 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Feb, 2024 | US10772888 |
|
Expire Patent
Critical
| 01 Jan, 2024 | US8067472 |
| Review Certificate Mailed | 19 Sep, 2023 | US7326708 (Litigated) |
| Review Certificate Mailed | 19 Sep, 2023 | US7326708 (Litigated) |
| Review Certificate | 06 Sep, 2023 | US7326708 (Litigated) |
| Review Certificate | 06 Sep, 2023 | US7326708 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 17 Jul, 2023 | US8067472 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2023 | US8093295 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2023 | US8080580 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2023 | US8080580 |
Msd Sub Merck's Drug Patent Litigations
Msd Sub Merck's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 17, 2014, against patent number US6635280. The petitioner Endo Pharmaceutical Inc. et al., challenged the validity of this patent, with Depomed, Inc. as the respondent. Click below to track the latest information on how companies are challenging Msd Sub Merck's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7326708 | June, 2020 |
Final Written Decision
(10 May, 2021)
| Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US7326708 | June, 2020 |
Final Written Decision
(10 May, 2021)
| Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
| US7326708 | October, 2019 |
Final Written Decision
(07 May, 2021)
| Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
| US7326708 | June, 2020 |
Terminated-Settled
(08 Dec, 2020)
| Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US6340475 | April, 2014 |
Final Written Decision
(21 Sep, 2015)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Final Written Decision
(21 Sep, 2015)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6340475 | January, 2014 |
FWD Entered
(08 Jul, 2015)
| Depomed, Inc. | Purdue Pharma L.P. |
| US6635280 | January, 2014 |
FWD Entered
(08 Jul, 2015)
| DepoMed, Inc. | Purdue Pharma L.P. |
| US6340475 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
Msd Sub Merck Drug Patents' Oppositions Filed in EPO
Msd Sub Merck drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 11, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04755691A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16198994A | Jan, 2020 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP16198994A | Dec, 2019 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP05852790A | Aug, 2017 | Georg Kalhammer/Stephan Teipel | Patent maintained as amended |
| EP05852790A | Aug, 2017 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Patent maintained as amended |
| EP05852839A | Aug, 2014 | Sölch, Günter | Patent maintained as amended |
| EP03711372A | May, 2013 | Generics [UK] Limited | Revoked |
| EP05077584A | Mar, 2011 | APOTEX INC. | Revoked |
| EP04755691A | Jun, 2008 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
Msd Sub Merck's Family Patents
Msd Sub Merck Drug List
Given below is the complete list of Msd Sub Merck's drugs and the patents protecting them.
1. Bridion
Bridion is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE44733 | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
27 Jan, 2026
(1 year, 3 months from now)
| Active |
| US6949527 | 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
27 Jan, 2021
(3 years ago)
| Expired |
| US7265009 | HDP-CVD methodology for forming PMD layer |
07 Aug, 2020
(4 years ago)
| Expired |
| US7265099 | Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
07 Aug, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bridion's drug page
2. Integrilin
Integrilin is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5807825 | Platelet aggregation inhibitors |
15 Sep, 2015
(9 years ago)
| Expired |
| US5968902 | Platelet aggregation inhibitors |
02 Jun, 2015
(9 years ago)
| Expired |
| US5747447 | Stable polypeptide composition |
05 May, 2015
(9 years ago)
| Expired |
| US5686570 | Platelet aggregation inhibitors |
11 Nov, 2014
(9 years ago)
| Expired |
| US5756451 | Platelet aggregation inhibitors |
11 Nov, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Integrilin's drug page
3. Invanz
Invanz is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5952323
(Pediatric)
| Carbapenem antibiotic |
15 Nov, 2017
(6 years ago)
| Expired |
| US5952323 | Carbapenem antibiotic |
15 May, 2017
(7 years ago)
| Expired |
| US5478820
(Pediatric)
| Antibiotic compounds |
21 May, 2016
(8 years ago)
| Expired |
| US5478820 | Antibiotic compounds |
21 Nov, 2015
(8 years ago)
| Expired |
| US5652233
(Pediatric)
| Antibiotic compounds |
02 Aug, 2013
(11 years ago)
| Expired |
| US7342005
(Pediatric)
| Antibiotic compounds |
02 Aug, 2013
(11 years ago)
| Expired |
| US5652233 | Antibiotic compounds |
02 Feb, 2013
(11 years ago)
| Expired |
| US7342005 | Antibiotic compounds |
02 Feb, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invanz's drug page
4. Isentress
Isentress is protected by 10 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8771733 | Pharmaceutical composition containing an anti-nucleating agent |
02 Jun, 2030
(5 years from now)
| Active |
| US7754731
(Pediatric)
| Potassium salt of an HIV integrase inhibitor |
11 Sep, 2029
(4 years from now)
| Active |
| US7754731 | Potassium salt of an HIV integrase inhibitor |
11 Mar, 2029
(4 years from now)
| Active |
| US8852632 | Pharmaceutical formulation containing a release rate controlling composition |
28 Jan, 2028
(3 years from now)
| Active |
| US7169780
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
03 Apr, 2024
(6 months ago)
| Expired |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
03 Oct, 2023
(1 year, 14 days ago)
| Expired |
| US7217713
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US7435734
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Oct, 2022
(1 year, 11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress's drug page
5. Isentress Hd
Isentress Hd is protected by 12 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10772888 | Solid pharmaceutical compositions containing an integrase inhibitor |
30 Mar, 2032
(7 years from now)
| Active |
| US9649311
(Pediatric)
| Solid pharmaceutical compositions containing an integrase inhibitor |
21 Apr, 2031
(6 years from now)
| Active |
| US9649311 | Solid pharmaceutical compositions containing an integrase inhibitor |
21 Oct, 2030
(6 years from now)
| Active |
| US8771733 | Pharmaceutical composition containing an anti-nucleating agent |
02 Jun, 2030
(5 years from now)
| Active |
| US7754731
(Pediatric)
| Potassium salt of an HIV integrase inhibitor |
11 Sep, 2029
(4 years from now)
| Active |
| US7754731 | Potassium salt of an HIV integrase inhibitor |
11 Mar, 2029
(4 years from now)
| Active |
| US7169780
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
03 Apr, 2024
(6 months ago)
| Expired |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
03 Oct, 2023
(1 year, 14 days ago)
| Expired |
| US7217713
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US7435734
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Oct, 2022
(1 year, 11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress Hd's drug page
Explore Our Curated Drug Screens
6. Janumet
Janumet is protected by 12 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8414921
(Pediatric)
| Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
21 Jan, 2029
(4 years from now)
| Active |
| US8414921 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
21 Jul, 2028
(3 years from now)
| Active |
| US7326708
(Pediatric)
| Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 May, 2027
(2 years from now)
| Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 Nov, 2026
(2 years from now)
| Active |
| US6699871
(Pediatric)
| Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(1 year, 8 months ago)
| Expired |
| US7125873
(Pediatric)
| Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(1 year, 8 months ago)
| Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet's drug page
7. Janumet Xr
Janumet Xr is protected by 12 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7326708
(Pediatric)
| Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 May, 2027
(2 years from now)
| Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 Nov, 2026
(2 years from now)
| Active |
| US6699871
(Pediatric)
| Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(1 year, 8 months ago)
| Expired |
| US7125873
(Pediatric)
| Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(1 year, 8 months ago)
| Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
| US6340475 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
| US6635280 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet Xr's drug page
8. Segluromet
Segluromet is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9308204 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
21 Oct, 2030
(6 years from now)
| Active |
| US9439902 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
21 Oct, 2030
(6 years from now)
| Active |
| US8080580 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
13 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Segluromet's drug page
9. Steglatro
Steglatro is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8080580 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
13 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglatro's drug page
10. Steglujan
Steglujan is protected by 10 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9308204 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
21 Oct, 2030
(6 years from now)
| Active |
| US9439901 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
21 Oct, 2030
(6 years from now)
| Active |
| US8080580 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
13 Jul, 2030
(5 years from now)
| Active |
| US7326708
(Pediatric)
| Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 May, 2027
(2 years from now)
| Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 Nov, 2026
(2 years from now)
| Active |
| US6699871
(Pediatric)
| Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(1 year, 8 months ago)
| Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglujan's drug page
11. Zepatier
Zepatier is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8871759 | Inhibitors of hepatitis C virus replication |
04 May, 2031
(6 years from now)
| Active |
| US7973040 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
24 Jul, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepatier's drug page
12. Zolinza
Zolinza is protected by 10 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8450372 | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
18 Mar, 2028
(3 years from now)
| Active |
| US7456219 | Polymorphs of suberoylanilide hydroxamic acid |
11 Mar, 2027
(2 years from now)
| Active |
| US8093295 | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
16 May, 2026
(1 year, 6 months from now)
| Active |
| US7399787 | Methods of treating cancer with HDAC inhibitors |
09 Feb, 2025
(3 months from now)
| Active |
| US7851509 | Polymorphs of suberoylanilide hydroxamic acid |
21 Feb, 2024
(7 months ago)
| Expired |
| US7652069 | Polymorphs of suberoylanilide hydroxamic acid |
04 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US7732490 | Methods of treating cancer |
04 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US8067472 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
04 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US8101663 | Polymorphs of suberoylanilide hydroxamic acid |
04 Mar, 2023
(1 year, 7 months ago)
| Expired |
| USRE38506 | Potent inducers of terminal differentiation and methods of use thereof |
29 Nov, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zolinza's drug page